Study of the Effects of STN-DBS on Gait in Parkinson's Disease.
Clinical Series Study of the Effects of STN-DBS on Gait in Parkinson's Disease Based on Wearable Devices.
1 other identifier
interventional
30
0 countries
N/A
Brief Summary
Objectives: Parkinson's disease (PD) is the second most common degenerative disease of the nervous system. Postural instability/gait disorder (PIGD) is one of the motor symptoms of Parkinson's disease, which affects the quality of life of patients with Parkinson's disease. At present, deep brain stimulation(DBS)can significantly improve tremor and bradykinesia, but whether deep brain stimulation is effective for gait disorders is still a controversial topic. In addition, the previous gait assessment mainly focused on scales or simple walking tests, and appropriate and effective evaluation methods are needed to evaluate the efficacy of intervention for gait disorders in PD patients. Therefore, in view of these problems, this study will use wearable devices and traditional scale evaluation to explore the effects of deep brain stimulation on gait in patients with Parkinson's disease. Methods: A total of 30 patients with Subthalamic nucleus DBS(STN-DBS)were expected to be enrolled. By adjusting the parameters of STN-DBS (voltage, frequency, pulse width), the effects of different parameters on PD gait were compared. Gait changes were mainly analyzed by wearable devices and MDS Unified Parkinson's Disease Rating Scale assessment(MDS-UPDRS). The (Timed Up and Go)TUG test, narrow channel task, circle task and trajectory analysis were performed in the unmedicated state. The wearable device was used to collect the motion information of 10 different positions of the human body, including the wrist, thigh, ankle, foot tip, chest and waist nodes. (1)Experiment 1: Patients were divided into pre-operation group and post-operation group. A case-control study was conducted, and patients were followed up at 1 month,3 months,6 months and 1 year after operation. (2)Experiment 2: This study was a single-center, randomized, double-blind, crossover trial of deep brain stimulation with a short pulse width (30s) versus conventional pulse width (60 s) in PD patients with bilateral STN-DBS. Gait data and MDS-UPDRS were collected at baseline, after 4 weeks and 8 weeks. (3)Experiment 3: By adjusting the frequency parameters of STN-DBS (30,100, and 130HZ), gait data and MDS-UPDRS were collected after 10 minutes of the washout period, and the best DBS parameters for gait improvement were maintained for 4-8 weeks and then evaluated again. Expected results: By adjusting the parameters (voltage, frequency, and pulse width) of STN-DBS, the potential mechanisms for improving gait disorders in PD were explored, meaningful digital biomarkers for PD gait prognosis were explored, and long-term programming of STN-DBS was guided.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable parkinson-disease
Started Jun 2024
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 14, 2024
CompletedFirst Posted
Study publicly available on registry
May 17, 2024
CompletedStudy Start
First participant enrolled
June 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2026
CompletedMay 17, 2024
March 1, 2024
1.5 years
May 14, 2024
May 14, 2024
Conditions
Outcome Measures
Primary Outcomes (3)
Gait data
Gait changes were analyzed by wearable devices and MDS-UPDRS.
Pre-operation(baseline),1 month,3 months,6 months and 1 year after operation.
Gait data
Gait changes were analyzed by wearable devices and MDS-UPDRS.
Baseline, after 4 weeks and 8 weeks.
Gait data
Gait changes were analyzed by wearable devices and MDS-UPDRS.
Baseline, after 10 minutes of the washout period, after4-8 weeks.
Study Arms (6)
Experiment 1: Experimental group 1
EXPERIMENTALPD Patient's gait were followed up at 1 month,3 months,6 months, and 1 year after bilateral STN-DBS surgery.
Experiment 1: Comparator group 1
ACTIVE COMPARATORPD patient's gait with optimal medical therapy before bilateral STN-DBS surgery.
Experiment 2: Experimental group 2
EXPERIMENTALPD patient's gait with a short pulse width (30s) with bilateral STN-DBS.
Experiment 2: Comparator group 2
ACTIVE COMPARATORPD patient's gait with the conventional pulse width (60 s) with bilateral STN-DBS.
Experiment 3: Experimental group 3
EXPERIMENTALPD patient's gait with frequency parameters(60,100, and 130HZ) with bilateral STN-DBS.
Experiment 3: Comparator group 3
ACTIVE COMPARATORPD patient's gait with the conventional frequency parameters with bilateral STN-DBS.
Interventions
bilateral subthalamic nucleus deep brain stimulation surgery
a short pulse width (30s)
frequency parameters of STN-DBS (60,100, and 130HZ)
Eligibility Criteria
You may qualify if:
- (1) Age 40-75 years old; (2) Patients who meet the Chinese Parkinson's disease diagnostic criteria and confirmed by two high-level physicians (\>10 years); (3) Diagnosed by Parkinson's Specialty Clinic For Parkinson's disease for more than 1 year and have been effective after treatment; (4) Hearing, visual and cognitive abilities are normal; (5) The subjects were informed of the test purpose, the benefits of the test, the test process and possible unexpected situations before the test , and signed the trial informed consent form.
You may not qualify if:
- (1) A variety of secondary Parkinson's syndrome (including traumatic, drug-induced, tumor, vascular, toxic, hydrocephalus, etc.) and Parkinson's superimposed syndrome. (2) Other diseases that cause gait disorders, including spinal joint injuries, muscle spasm, stroke, peripheral neuropathy, muscle diseases, hydrocephalus, cognitive impairment, etc. (3) Accompanied by vital organ (heart, lung, liver, kidney, etc.) failure, malignant tumors, unstable conditions and other serious medical diseases. (4) Those who have serious behavior problems or mental confusion. (5)Those who do not cooperate with the examination.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 14, 2024
First Posted
May 17, 2024
Study Start
June 1, 2024
Primary Completion
December 1, 2025
Study Completion
March 1, 2026
Last Updated
May 17, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share